96 related articles for article (PubMed ID: 35837977)
1. Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
Matsuda S; Kitagawa Y; Takemura R; Okui J; Okamura A; Kawakubo H; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Ann Surg; 2023 Jul; 278(1):e35-e42. PubMed ID: 35837977
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Nagai Y; Asami C; Kitagawa Y
Br J Cancer; 2016 Nov; 115(11):1328-1334. PubMed ID: 27811857
[TBL] [Abstract][Full Text] [Related]
3. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).
Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y
PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652
[TBL] [Abstract][Full Text] [Related]
4. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
Liu J; Zhu L; Huang X; Lu Z; Wang Y; Yang Y; Ye J; Gu C; Lv W; Zhang C; Hu J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):161. PubMed ID: 38536527
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003).
Sugimura K; Yamasaki M; Yasuda T; Yano M; Hirao M; Fujitani K; Kimura Y; Miyata H; Motoori M; Takeno A; Shiraishi O; Makino T; Kii T; Tanaka K; Satoh T; Mori M; Doki Y
Ann Gastroenterol Surg; 2021 Jan; 5(1):75-82. PubMed ID: 33532683
[TBL] [Abstract][Full Text] [Related]
6. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P; Gricar J; Zhang Y; Shankaran V
Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study.
Xie SH; Yang LT; Zhang H; Tang ZL; Lin ZW; Chen Y; Hong ZN; Xu RY; Lin WL; Kang MQ
Front Immunol; 2024; 15():1332492. PubMed ID: 38375480
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC).
Shiozaki A; Kudou M; Fujiwara H; Konishi H; Shimizu H; Arita T; Kosuga T; Yamamoto Y; Morimura R; Ikoma H; Kuriu Y; Kubota T; Okamoto K; Otsuji E
Medicine (Baltimore); 2020 Dec; 99(50):e23633. PubMed ID: 33327342
[TBL] [Abstract][Full Text] [Related]
9. Comparing the Efficacy of Carboplatin plus 5-Fluorouracil, Cisplatin plus 5-Fluorouracil, and Best Supportive Care for Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Analysis from a Tertiary Hospital in Southern Thailand.
Wonglhow J; Wetwittayakhlang P; Sunpaweravong P; Sathitruangsak C; Dechaphunkul A
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541960
[No Abstract] [Full Text] [Related]
10. Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma.
Nie X; He S; Nie X; Li C; Du K; He W; Li Z; Ni K; Lu S; Wang C; Wang K; Miao Y; Jiang L; Lv J; Liu G; Fang Q; Peng L; Xiao W; Wang Q; Wang D; Han Y; Leng X
Front Immunol; 2023; 14():1320282. PubMed ID: 38179053
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer.
Hashiguchi T; Nasu M; Hashimoto T; Kuniyasu T; Inoue H; Sakai N; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Tsurumaru M; Kajiyama Y
Mol Clin Oncol; 2014 Sep; 2(5):719-724. PubMed ID: 25054036
[TBL] [Abstract][Full Text] [Related]
12. Utility of Initial Tumor Reduction as a Prognostic Factor in Esophageal Squamous Cell Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery : A Retrospective Cohort Study.
Hagi T; Shiraishi O; Nakanishi T; Kohda M; Hiraki Y; Kato H; Yasuda A; Shinkai M; Imano M; Yasuda T
Ann Surg Oncol; 2024 Apr; ():. PubMed ID: 38664331
[TBL] [Abstract][Full Text] [Related]
13. Comment on "Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study".
Gronnier C
Ann Surg Oncol; 2024 May; 31(5):2815-2817. PubMed ID: 38355781
[No Abstract] [Full Text] [Related]
14. Current management of esophageal squamous-cell carcinoma in Japan and other countries.
Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Azuma M; Nakatani K; Ishido K; Naruke A; Ryu T
Gastrointest Cancer Res; 2009 Jul; 3(4):153-61. PubMed ID: 19742141
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment for esophageal squamous cell carcinoma.
Baba Y; Watanabe M; Yoshida N; Baba H
World J Gastrointest Oncol; 2014 May; 6(5):121-8. PubMed ID: 24834142
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinoma of the anus successfully treated with multidisciplinary therapy for metachronous metastatic and local recurrences after DCF chemotherapy: a case report.
Naito R; Shiraishi T; Hosoi N; Watanabe T; Shioi I; Shibasaki Y; Nakazawa N; Osone K; Okada T; Sano A; Sakai M; Ogawa H; Sohda M; Shirabe K; Saeki H
Surg Case Rep; 2024 Mar; 10(1):71. PubMed ID: 38526705
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
[TBL] [Abstract][Full Text] [Related]
19. Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.
Tsuji T; Matsuda S; Takeuchi M; Kawakubo H; Kitagawa Y
Jpn J Clin Oncol; 2023 Jul; 53(8):645-652. PubMed ID: 37282626
[TBL] [Abstract][Full Text] [Related]
20. Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers.
Matsuda S; Kitagawa Y; Okui J; Okamura A; Kawakubo H; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Esophagus; 2023 Jul; 20(3):445-454. PubMed ID: 36662353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
